新药ION224在试验中改善了60%的MASH患者的肝脏健康,为扭转脂肪肝病带来了希望。 A new drug, ION224, improved liver health in 60% of MASH patients in a trial, offering hope for reversing fatty liver disease.

以肝酶DGAT2为对象的新调查药物IMON224显示,治疗与肥胖和可能导致肝硬化、肝衰竭或癌症的2型糖尿病有关的严重脂肪性肝病MASH(一种与肥胖症有关的严重脂肪性肝病)很有希望。 A new investigational drug, ION224, targeting the liver enzyme DGAT2, shows promise in treating MASH, a severe fatty liver disease linked to obesity and type 2 diabetes that can lead to cirrhosis, liver failure, or cancer. 在对160名有早期至中度纤维化的成人进行的第二阶段b试验中,60%的参与者使用的最高剂量改善了肝脏健康,减少了脂肪和炎症,没有产生严重的副作用。 In a Phase IIb trial of 160 adults with early to moderate fibrosis, the highest dose improved liver health in 60% of participants, reducing fat and inflammation without serious side effects. 药物的好处无论重量变化如何都会发生,这表明有可能成为一种独立或补充疗法。 The drug’s benefits occurred regardless of weight change, suggesting potential as a standalone or complementary therapy. 如果在更大的试验中得到确认,INON224可成为MASH中第一个停止或扭转肝脏损害的治疗方法,这在管理这一日益增长的健康关切方面是一个重大进步。 If confirmed in larger trials, ION224 could become the first treatment to halt or reverse liver damage in MASH, offering a major advance in managing this growing health concern.